Over 1,000 Chemotherapy Protocols And Counting
New chemotherapy protocols are added weekly. All protocols are reviewed by Medical Oncologists and Hematologists.
New Reference: Afatinib for NSCLC with Uncommon EGFR Mutations
Open-label, randomized, multicenter phase 3 trial (ACHILLES/TORG1834) Previously untreated non-squamous NSCLC with sensitizing uncommon EGFR mutations (excluding exon20ins and T790
New Indication: Datopotamab Deruxtecan in NSCLC with Actionable Mutations
Phase II, single-arm, open-label study (TROPION-Lung05) Advanced/metastatic NSCLC with actionable genomic alterations Datopotamab deruxtecan 6mg/kg Q3W
New Reference: Sacituzumab Govitecan for Advanced Urothelial Carcinoma
Phase 3, randomized, open-label trial (TROPiCS-04) Previously treated advanced urothelial carcinoma (progression after platinum-based chemotherapy and checkpoint inhibitor) Sacituz
New Reference: Ipilimumab / Nivolumab for Non-Clear Cell RCC
Phase 2, multicenter, randomized trial (SUNNIFORECAST) Previously untreated advanced/metastatic non-clear cell RCC Ipilimumab + nivolumab (4 cycles) followed by nivolumab maintenan
New Reference: Neoadjuvant FOLFIRNOX for Pancreatic Cancer
Multicenter, randomized, noncomparative phase 2 trial (PANACHE01 FRENCH08 PRODIGE48) Resectable pancreatic adenocarcinoma patients Neoadjuvant mFOLFIRINOX (4 cycles) vs. neoadjuvan
New Reference: Talquetamab for Relapsed/Refractory Multiple Myeloma
Multicentre, open-label, phase 1–2 study (MonumenTAL-1) Relapsed/refractory multiple myeloma pts with ≥3 prior lines of therapy Talquetamab 0.4 mg/kg weekly or 0.8 mg/kg every
New Reference: SOX for Gastric/GEJ AdenoCa
Open-label, randomized, phase 3 trial (RESOLVE) Patients with cT4a N+ M0 or cT4b Nany M0 gastric or gastro-oesophageal junction adenocarcinoma after D2 gastrectomy Perioperative SO
New Protocol: Brentuximab-Rituximab-Lenalidomide for Large Cell Lymphoma
Phase 3, randomized, double-blind, placebo-controlled trial (ECHELON-3) Relapsed or refractory DLBCL after ≥2 lines of therapy, ineligible for or relapsed after SCT or CAR T-cell
New Indication: Adjuvant Pembrolizumab for Bladder Cancer
Phase 3, open-label, randomized trial (AMBASSADOR) High-risk muscle-invasive urothelial carcinoma after radical surgery Pembrolizumab (200 mg q3w for 1 yr) vs. observation
